TABLE 1.
Cancer vaccination clinical trials for head and neck squamous cell carcinoma
| Vaccine type/target antigens | Adjuvants/other therapy | Type | Phase | Identifier | Period | Reference |
|---|---|---|---|---|---|---|
| Pre/active trials | ||||||
| ADXS11‐001 (HPV 16‐E6/E7) | Viral Ag | II | NCT02002182 | Dec 2013‐Aug 2022 | 82 | |
| MUC1 peptide | PDE5 inhibitor | TAA | I/II | NCT02544880 | Apr 2016‐Jun 2020 | 83 |
| DPX‐E7 (HPV 16‐E7 11‐19 nanomer) | Cyclophosphamide | Viral Ag | I | NCT02865135 | Dec 2016‐Dec 2020 | |
| MVX‐ONCO1 (irradiated tumor cell lysate) | GM‐CSF | Cellular | II | NCT02999646 | Jun 2017‐Dec 2024 | |
| TG4001 (HPV 16‐E6/E7 coded vector) | Avelumab | Viral Ag | I/II | NCT03260023 | Sep 2017‐May 2021 | |
| E6/E7 RNA | Anti‐CD40 | Viral Ag | I/II | NCT03418480 | Apr 2017‐Dec 2020 | |
| Tumor‐derived neoantigens | Anti‐PD‐1 | TSA | I | NCT03568058 | Jul 2018‐Aug 2023 | |
| Arginase1 peptide | Montanide ISA‐51 | TAA | I | NCT03689192 | Dec 2018‐Jun 2021 | |
| PepCan (HPV‐16 E6 peptides) | Viral Ag | I/II | NCT03821272 | Nov 2019‐Sep 2021 | ||
| Autologous tumor antigen (TriAD) | Anti‐PD‐L1, TGF‐β, GM‐CSF | TAA | I/II | NCT04247282 | Apr 2020‐Dec 2021 | |
| PANDA‐VAC (neoantigen peptides) | PolyICLC, pembrolizumab | TSA | I | NCT04266730 | Sep 2020 | |
| HPV‐16 E6/E7 peptides | Cisplatin‐IMRT, pembrolizumab | Viral Ag | II | NCT04369937 | May 2020‐Jun 2022 | |
| Completed | ||||||
| HPV‐16 E6/E7 peptides | Viral Ag | I | NCT00019110 | Nov 1995 | ||
| Ras protein | IL‐2, sargramostim | TAA | II | NCT00019331 | Oct 1997‐May 2007 | |
| B7‐1, ICAM1, LFA‐1 transgenes (TRICOM) | TAA | I | NCT00021424 | Jun 2001 | ||
| TRICOM‐CEA peptide | TAA | I | NCT00027534 | January 2002‐October 2007 | ||
| MAGE‐A3/ HPV‐16 peptides | GM‐CSF, IFA | TAA/viral Ag | I | NCT00257738 | Nov 2005‐Oct 2012 | 40 |
| Modified p53 pulsed dendritic cells | Th tetanus toxoid | TAA | I | NCT00404339 | Mar 2011‐Mar 2014 | 37 |
| MVA‐EL (EBV‐EBNA/LMP2) | Viral Ag | I | NCT01147991 | Mar 2005‐Apr 2011 | 50, 51 | |
| VicOryx trial (p16 peptides) | Montanide ISA‐51 | TAA | I/II | NCT01462838 | Aug 2011‐May 2015 | |
| AlloVAX: chaperone rich cell lysate | AlloStim (adjuvant) | Cellular | II | NCT01998542 | Jan 2016‐Nov 2017 | |
| HPV‐E7 | Surgery (TOVS) | Viral Ag | II | NCT02002182 | Dec 2013‐Aug 2019 | |
| MEDI‐0457 (HPV16/18‐E6/E7) | Cisplatin or surgery | Viral Ag | I/II | NCT02163057 | Jun 2014‐Nov 2017 | |
| HPV‐E7 | Durvalumab | Viral Ag | I/II | NCT02291055 | Apr 2015‐Dec 2019 | |
| ISA 101 (HPV16‐E6/E7) | Nivolumab | Viral Ag | II | NCT02426892 | Dec 2015‐Dec 2016 | 47 |
| VicOryx‐2 trial (p16 peptides) | Montanide ISA‐51, cisplatin | TAA | I | NCT02526316 | Jun 2015‐May 2017 | |
| MEDI‐0457 (HPV16/18‐E6/E7) | Durvalumab | Viral Ag | I/II | NCT03162224 | Jun 2017‐Aug 2019 | |
| Survivin‐2B peptide | TAA | I | UMIN000000976 | Sep 2003‐Jul 2006 | 84 | |
| LY6K, CDCA1, IMP3 peptides | IFA | TAA | I/II | UMIN000008379 | Dec 2008 | 41 |
Abbreviations: Ag, antigen; GM‐CSF, granulocyte/macrophage colony‐stimulating factor; HPV, human papillomavirus; IL, interleukin; IMRT, intensity‐modulated radiation therapy; PD‐1, programmed cell death‐1; PD‐L1, PD‐1 ligand; PDE5, phosphodiesterase‐5; polyICLC, polyinosinic‐polycytidylic acid mixed with the stabilizers carboxymethylcellulose and polylysine; TAA, tumor‐associated antigen; TGF‐β, transforming growth factor‐β; TOVS, trans oval videolaryngoscopic surgery; TSA, tumor‐specific antigen.